UK: FSA to debate options for children's food ads
The UK's Food Standards Agency has published a discussion paper on possible options for action on the promotion and advertising of foods that could improve children's diets and health.
Action under consideration includes research, building on existing guidance, best practice, and new regulation. These measures could cover sponsorship, advertising, labelling, endorsements, in-store activity and loyalty schemes, the agency said.
The board of the FSA is to decide next year, following public debate, which policy options it wishes to recommend to the government.
In September 2003, the FSA published an independent research project 'Does Food Promotion Influence Children? A Systematic Review of the Evidence', carried out by Professor Gerard Hastings. His review concluded that advertising to children does have an effect on children's food preferences, purchase behaviour and consumption, and that these effects occur not just at brand level, but also for different types of foods.
"We already know that many children's diets contain more fat, sugar and salt than is recommended. We know that the level of obesity in children is rising and, in the words of the Chief Medical Officer, is a health time bomb that could explode. By 2010 it could cost £3.6bn a year and be a very significant factor in the ill health of thousands of people and their families. This is why the agency is encouraging a wide debate on the options for action that could make a difference. Doing nothing is not an option," said Sir John Krebs, chair of the Food Standards Agency.
Martin Paterson, director general of the Food and Drink Federation, which represents the food and drinks industry, welcomed the opportunity for discussion.
"We welcome the opportunity to continue our participation in this important debate with FSA, the Department of Health and other stakeholders. The promotion of food and drink to children is already highly regulated. Strict codes of practice exist to govern advertising: currently advertisements may not encourage children to eat or drink frequently throughout the day; condone excessive consumption; or suggest that confectionery or snacks should replace balanced meals," Paterson said.
Companies: Food and Drink Federation
Artificial sweetener Splenda has enjoyed phenomenal success in recent years, and now has a 51% share of the US market. But now it has a fight on its hands, as sugar manufacturers file lawsuits claimin...
Obese people can be fitted with a device that fools their brain into thinking they have eaten to help them lose weight, according to a BBC report....
Doctors' group the British Medical Association has called for a serious of measures to combat childhood obesity including no 'junk' food advertising or sponsorship and bans on 'unhealthy' food and dri...
The Food Standards Agency has commissioned new work to examine refinements to its nutrient profiling model....
The Food Standards Agency has announced a £10m to be paid to local authorities in England to promote a new food safety initiative....
The Food Standards Agency has announced the setting up of an incidents task force to strengthen existing controls in the food chain in order to reduce the possibility of future contamination incidents...
The Food Standards Agency (FSA) today announced the launch of the largest research project it has undertaken to date, to look at what consumers would like to see on front-of-pack labelling....
Biotechnology company Cytos Biotechnology AG has announced the start of clinical trials of CYT009-GhrQb, a therapeutic vaccine for the treatment of obesity....
- Who will buy Danone's Stonyfield business?
- Analysis: Post discusses rationale for Weetabix
- US food next wave on display at Winter Fancy Food
- Why personalisation will take-off in US food
- Interview: Sir Kensington's on sale to Unilever
- Update - Post Holdings confirms Weetabix deal
- Unilever buys US condiments maker Sir Kensington's
- Ice cream helps Unilever sales, food flat
- Post: Weetabix "opens up M&A opportunities"
- Post Holdings 'secures Weetabix' in US$1.76bn deal